Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
The DOI matches its Crossref record; 163 of the 163 references it cites were found in a registry or an index.
Abstract
Increased generation of reactive oxygen species (ROS) and an altered redox status have long been observed in cancer cells, and recent studies suggest that this biochemical property of cancer cells can be exploited for therapeutic benefits. Cancer cells in advanced stage tumours frequently exhibit multiple genetic alterations and high oxidative stress, suggesting that it might be possible to preferentially eliminate these cells by pharmacological ROS insults. However, the upregulation of antioxidant capacity in adaptation to intrinsic oxidative stress in cancer cells can confer drug resistance. Abrogation of such drug-resistant mechanisms by redox modulation could have significant therapeutic implications. We argue that modulating the unique redox regulatory mechanisms of cancer cells might be an effective strategy to eliminate these cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, available data suggest that MGF-driven restoration of redox homeostasis represents a central mechanistic axis of its antitumor activity, rather than merely a downstream branch of apoptosis (84,85).”
From Mangiferin in human disease: Multifaceted mechanisms and applications (Review) (2026) · cites this paper as [84]
In the citing paper
“Activation of oncogenes, aberrant metabolism, mitochondrial dysfunction, and loss of the tumor suppressor p53 can all promote increased ROS accumulation in cancer cells 69.”
From Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes (2010) · cites this paper as [69]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379 · cited 1×
“It has been observed that a small subpopulation of primary cancer cells expressing stem-cell markers was resistant to certain chemotherapeutic agents and radiatio”
BackgroundSchafer, F. Q., & Buettner, G. R. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00480-4 · Cited by 4,587 · cited 1×
“A moderate increase in ROS can promote cell proliferation and differentiatio”
BackgroundFive-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488 · cited 1×
“By exploiting the genetic differences between normal cells and cancer cells, several molecular-targeted drugs, such as imatinib (Gleevec; Novartis) and trastuzumab (Herceptin; Genentech/Roche), show promising therapeutic activity and few toxic side effect”
BackgroundCancer stem cells in solid tumours: accumulating evidence and unresolved questions
Visvader, J. E., & Lindeman, G. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2499 · Cited by 3,429 · cited 1×
“Redox status in cancer stem cells Recurrence of cancer after chemotherapy or radiotherapy is initiated by a subpopulation of residual malignant cells that are highly resistant to treatment and which are believed to be cancer-initiating cells or cancer stem cell”
Background(2012) · Hepatogastroenterology · doi:10.5754/hge12469 · Cited by 3,178
Production of large amounts of hydrogen peroxide by human tumor cells.
Szatrowski, T. P., & Nathan, C. (1991) · PubMed · Cited by 3,007
Association of reactive oxygen species levels and radioresistance in cancer stem cells
Diehn, M., Cho, R. W., Lobo, N. A., Kalisky, T., Dorie, M. J., Kulp, A. N., Qian, D., Lam, J. S., Ailles, L. E., Wong, M., et al. (2009) · Nature · doi:10.1038/nature07733 · Cited by 2,555 · cited 1×
“Recent studies showed that normal haemopoietic stem cells and normal mammary epithelial stem cells maintained ROS at lower levels than their mature progeny to prevent cellular differentiation and maintain long-term self-renewa”
BackgroundBjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., & Gluud, C. (2007) · JAMA · doi:10.1001/jama.297.8.842 · Cited by 2,275
Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,272 · cited 1×
“This is consistent with the high incidence of p53 mutation or loss of p53 function in over 50% of human cancer”
Background
Research works printed but not linked: 1
- Kim, G. J., Chandrasekaran, K. & Morgan, W. F. Mitochondrial dysfunction, persistently elevated levels of reactive oxygen species and radiation-induced genomic instability: a review. Mutagenesis 21, 361–367 (2006). · DOI · Paper page
Cited by
Ayala, A., Muñoz, M. F., & Argüelles, S. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/360438 · Cited by 6,349
Reactive oxygen species (ROS) as pleiotropic physiological signalling agents
Sies, H., & Jones, D. P. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0230-3 · Cited by 5,335
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
“In the absence of the redox maintenance pathway that is supported by these tumour suppressors, malignant cells might be selectively kille”
BackgroundReactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling
Ray, P. D., Huang, B.-W., & Tsuji, Y. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.01.008 · Cited by 4,373
Modulation of oxidative stress as an anticancer strategy
Gorrini, C., Harris, I. S., & Mak, T. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4002 · Cited by 3,579
Reactive oxygen species in cancer
Liou, G.-Y., & Storz, P. (2010) · Free Radical Research · doi:10.3109/10715761003667554 · Cited by 3,382
“However, it is possible that a threshold of toxicity in these cancer cells is not reached and that the additional increase in ROS further causes more mutations or drives cell migration and invasion [221, 273].”
BackgroundInfluentialCystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy
Koppula, P., Zhuang, L., & Gan, B. (2021) · Protein & Cell · doi:10.1007/s13238-020-00789-5 · Cited by 2,487
Targeting Ferroptosis to Iron Out Cancer
Hassannia, B., Vandenabeele, P., & Vanden Berghe, T. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.04.002 · Cited by 2,478
Reactive Oxygen Species (ROS)-Based Nanomedicine
Yang, B., Chen, Y., & Shi, J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00626 · Cited by 2,443
The role of iron and reactive oxygen species in cell death
Dixon, S. J., & Stockwell, B. R. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1416 · Cited by 2,381
Antioxidants Maintain Cellular Redox Homeostasis by Elimination of Reactive Oxygen Species
He, L., He, T., Farrar, S., Ji, L., Liu, T., & Ma, X. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000485089 · Cited by 2,127
ROS in cancer therapy: the bright side of the moon
Perillo, B., Di Donato, M., Pezone, A., Di Zazzo, E., Giovannelli, P., Galasso, G., Castoria, G., & Migliaccio, A. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0384-2 · Cited by 2,176
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
Zhou, Z., Song, J., Nie, L., & Chen, X. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00271d · Cited by 2,098
Serine, glycine and one-carbon units: cancer metabolism in full circle
Locasale, J. W. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3557 · Cited by 1,673
Beyond oxidative stress: an immunologist's guide to reactive oxygen species
Nathan, C., & Cunningham-Bussel, A. (2013) · Nature Reviews Immunology · doi:10.1038/nri3423 · Cited by 1,619
Graves, D. B. (2012) · Journal of Physics D: Applied Physics · doi:10.1088/0022-3727/45/26/263001 · Cited by 1,518
“Figure 27 (following Trachootham et al [139]), illustrates the basic idea.”
BackgroundInfluentialMulti-Omics Factor Analysis—a framework for unsupervised integration of multi-omics data sets
Argelaguet, R., Velten, B., Arnol, D., Dietrich, S., Zenz, T., Marioni, J. C., Buettner, F., Huber, W., & Stegle, O. (2018) · Molecular Systems Biology · doi:10.15252/msb.20178124 · Cited by 1,510
“Although genes in HSP pathways are up-regulated in some cancers and have known roles in tumour cell survival (Trachootham et al , 2009), thus far this gene family has received little attention in the context of CLL. Consistent with this annotation based on the mRNA data, we observed that the drugs…”
Lin, L., Song, J., Song, L., Ke, K., Liu, Y., Zhou, Z., Shen, Z., Li, J., Yang, Z., Tang, W., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201712027 · Cited by 1,466
Lagadinou, E. D., Sach, A., Callahan, K., Rossi, R. M., Neering, S. J., Minhajuddin, M., Ashton, J. M., Pei, S., Grose, V., O’Dwyer, K. M., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2012.12.013 · Cited by 1,399
“This notion has provided the impetus to explore redox modulation as a therapeutic target in cancer, with the rationale that pro-oxidants may eradicate tumor cells by pushing them beyond the limits of viability (Trachootham et al., 2009).”
BackgroundConnecting copper and cancer: from transition metal signalling to metalloplasia
Ge, E. J., Bush, A. I., Casini, A., Cobine, P. A., Cross, J. R., DeNicola, G. M., Dou, Q. P., Franz, K. J., Gohil, V. M., Gupta, S., et al. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00417-2 · Cited by 1,298
Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements
Aggarwal, V., Tuli, H., Varol, A., Thakral, F., Yerer, M., Sak, K., Varol, M., Jain, A., Khan, M., & Sethi, G. (2019) · Biomolecules · doi:10.3390/biom9110735 · Cited by 1,221
“Some studies have also indicated that administration of therapeutic agents increasing ROS production along with conventional chemotherapies, have shown increased efficacy in targeting tumor cells [175,191,192].”
BackgroundIshimoto, T., Nagano, O., Yae, T., Tamada, M., Motohara, T., Oshima, H., Oshima, M., Ikeda, T., Asaba, R., Yagi, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.038 · Cited by 1,192
“High levels of GSH as well as increased expression of antioxidant enzymes promote cancer cell survival and resistance to anticancer agents (Trachootham et al., 2009).”
BackgroundThe Role of Reactive Oxygen Species (ROS) in the Biological Activities of Metallic Nanoparticles
Abdal Dayem, A., Hossain, M., Lee, S., Kim, K., Saha, S., Yang, G.-M., Choi, H., & Cho, S.-G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010120 · Cited by 1,141
“The main sources of intracellular ROS are mitochondria, the endoplasmic reticulum (ER), peroxisomes, microsomes, and NOX complexes (seven distinct isoforms) in cell membranes (Figure 1A) [33,34].”
Vatansever, F., de Melo, W. C. M. A., Avci, P., Vecchio, D., Sadasivam, M., Gupta, A., Chandran, R., Karimi, M., Parizotto, N. A., Yin, R., et al. (2013) · FEMS Microbiology Reviews · doi:10.1111/1574-6976.12026 · Cited by 1,127
“…limited to atherosclerosis (Paravicini & Touyz, 2006), diabetes (Paravicini & Touyz, 2006), carcinogenesis, and tumor metastasis through gene activation (Ishikawa et al., 2008; Trachootham et al., 2009), neurodegeneration (Andersen, 2004; Shukla et al., 2011), and aging (Haigis & Yankner, 2010).”
BackgroundTargeting Free Radicals in Oxidative Stress-Related Human Diseases
Poprac, P., Jomova, K., Simunkova, M., Kollar, V., Rhodes, C. J., & Valko, M. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.04.005 · Cited by 1,107
“However, it has been shown more recently that targeting the vital mechanisms which maintain the survival of cancer cells is a promising approach for cancer therapy [11].”
BackgroundNRF2 and cancer: the good, the bad and the importance of context
Sporn, M. B., & Liby, K. T. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3278 · Cited by 1,067
Selective killing of cancer cells by a small molecule targeting the stress response to ROS
Raj, L., Ide, T., Gurkar, A. U., Foley, M., Schenone, M., Li, X., Tolliday, N. J., Golub, T. R., Carr, S. A., Shamji, A. F., et al. (2011) · Nature · doi:10.1038/nature10167 · Cited by 1,030
“Our results demonstrate the ability of a small molecule to induce apoptosis selectively in cells that have a cancer genotype, by targeting a non-oncogene co-dependency acquired through the expression of the cancer genotype in response to transformation-induced oxidative stres”
RetractedMitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes
Hamanaka, R. B., & Chandel, N. S. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.04.002 · Cited by 1,011
Electrochemical Methods for the Analysis of Clinically Relevant Biomolecules
Labib, M., Sargent, E. H., & Kelley, S. O. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00220 · Cited by 976
Harris, I. S., Treloar, A. E., Inoue, S., Sasaki, M., Gorrini, C., Lee, K. C., Yung, K. Y., Brenner, D., Knobbe-Thomsen, C. B., Cox, M. A., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.019 · Cited by 993
Reich, H. J., & Hondal, R. J. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00031 · Cited by 923
Puente, B. N., Kimura, W., Muralidhar, S. A., Moon, J., Amatruda, J. F., Phelps, K. L., Grinsfelder, D., Rothermel, B. A., Chen, R., Garcia, J. A., et al. (2014) · Cell · doi:10.1016/j.cell.2014.03.032 · Cited by 909
“In contrast, ROS-mediated senescence and cell-cycle exit is a well-recognized characteristic of stem cells (Takahashi et al., 2006; Trachootham et al., 2009).”
Chen, H., Tian, J., He, W., & Guo, Z. (2015) · Journal of the American Chemical Society · doi:10.1021/ja511420n · Cited by 813
Lu, J., Tan, M., & Cai, Q. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.04.001 · Cited by 795
“To counter the deleterious effect of ROS, cells express anti-oxidants including anti-oxidant enzymes to detoxify ROS and prevent them from accumulating at high concentrations [38].”
BackgroundPyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis
Anastasiou, D., Yu, Y., Israelsen, W. J., Jiang, J.-K., Boxer, M. B., Hong, B. S., Tempel, W., Dimov, S., Shen, M., Jha, A., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1060 · Cited by 816
An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma
Hakimi, A. A., Reznik, E., Lee, C.-H., Creighton, C. J., Brannon, A. R., Luna, A., Aksoy, B. A., Liu, E. M., Shen, R., Lee, W., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.004 · Cited by 798
“…was not only associated with poor clinical outcome but also enriched in somatic alterations of central redox regulators KEAP1 and NRF2 (Jaramillo and Zhang, 2013), supporting the proposed roles of reactive oxygen species (ROS) and altered redox state in certain cancers (Trachootham et al., 2009).”
Gupta, S. C., Hevia, D., Patchva, S., Park, B., Koh, W., & Aggarwal, B. B. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4414 · Cited by 732
“On the other hand, normal cells appear to have, under lower basal stress and reserve, a higher capacity to cope with additional ROS-generating insults than cancer cells do (271, 300).”
Biomedicine Meets Fenton Chemistry
Tang, Z., Zhao, P., Wang, H., Liu, Y., & Bu, W. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00977 · Cited by 745
ROS signaling under metabolic stress: cross-talk between AMPK and AKT pathway
Zhao, Y., Hu, X., Liu, Y., Dong, S., Wen, Z., He, W., Zhang, S., Huang, Q., & Shi, M. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0648-1 · Cited by 735
“Even though cancer cells exhibit an enhanced antioxidant system, they still maintain higher ROS levels than normal cells [20, 109].”
Vazquez, F., Lim, J.-H., Chim, H., Bhalla, K., Girnun, G., Pierce, K., Clish, C. B., Granter, S. R., Widlund, H. R., Spiegelman, B. M., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.020 · Cited by 715
“On the other hand, above a certain threshold, ROS can be toxic and induce cellular damage, leading to cell death (Trachootham et al., 2009; Diehn et al., 2009).”
Targeting ROS in cancer: rationale and strategies
Glorieux, C., Liu, S., Trachootham, D., & Huang, P. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00979-4 · Cited by 651
“Redox modulation has long been considered a promising strategy for cancer treatment, but conflicting preclinical and clinical results have been observed 5,243,244,262 , suggesting a need to carefully evaluate different experimental models and clinical settings.”
Self-citationOxidative Stress in Cancer Cell Metabolism
Arfin, S., Jha, N. K., Jha, S. K., Kesari, K. K., Ruokolainen, J., Roychoudhury, S., Rathi, B., & Kumar, D. (2021) · Antioxidants · doi:10.3390/antiox10050642 · Cited by 665
“The cell’s defense against ROS includes antioxidant enzymes that detoxify ROS and prevent them from accumulating at high concentrations [167].”
BackgroundChemodynamic Therapy via Fenton and Fenton‐Like Nanomaterials: Strategies and Recent Advances
Jia, C., Guo, Y., & Wu, F. (2022) · Small · doi:10.1002/smll.202103868 · Cited by 685
Ali, A., Shah, T., Ullah, R., Zhou, P., Guo, M., Ovais, M., Tan, Z., & Rui, Y. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.629054 · Cited by 650
“In recent years, ROS-mediated cancer treatment based on in situ ROS generation has gained widespread research interest (Trachootham et al., 2009).”
BackgroundGlorieux, C., & Calderon, P. B. (2017) · Biological Chemistry · doi:10.1515/hsz-2017-0131 · Cited by 660
“For instance, glutathione (GSH) levels may be decreased either by its direct binding with phenylethylisothiocyanate (PEITC) and sulphoraphane (Trachootham et al., 2009) or by inhibition of γ-glutamylcysteine synthetase activity (a key enzyme involved in GSH synthesis) as done by Buthionine…”
MethodROS and diseases: role in metabolism and energy supply
Yang, S., & Lian, G. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-019-03667-9 · Cited by 658
Mitochondria and Mitochondrial ROS in Cancer: Novel Targets for Anticancer Therapy
Yang, Y., Karakhanova, S., Hartwig, W., D'Haese, J. G., Philippov, P. P., Werner, J., & Bazhin, A. V. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25349 · Cited by 672
“It is possible that there is a “vicious cycle” between ROS production, mtDNA mutations, genomic instability, and cancer development (Trachootham et al., 2009; Hamanaka and Chandel, 2010; Klaunig et al., 2011) (Fig.”
BackgroundReactive‐Oxygen‐Species‐Responsive Drug Delivery Systems: Promises and Challenges
Saravanakumar, G., Kim, J., & Kim, W. J. (2017) · Advanced Science · doi:10.1002/advs.201600124 · Cited by 675
Modulating ROS to overcome multidrug resistance in cancer
Cui, Q., Wang, J.-Q., Assaraf, Y. G., Ren, L., Gupta, P., Wei, L., Ashby, C. R., Yang, D.-H., & Chen, Z.-S. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.11.001 · Cited by 661
Seyfried, T. N., & Shelton, L. M. (2010) · Nutrition & Metabolism · doi:10.1186/1743-7075-7-7 · Cited by 644
“Mitochondrial dysfunction also increases levels of cytoplasmic calcium, the multi-drug resistance phenotype, production of reactive oxygen species, and abnormalities in iron-sulfur complexes, which together would further accelerate aberrant RTG signaling and genome mutability [85,106,107,110,111,120-122].”
BackgroundTom20 senses iron-activated ROS signaling to promote melanoma cell pyroptosis
Zhou, B., Zhang, J.-Y., Liu, X.-S., Chen, H.-Z., Ai, Y.-L., Cheng, K., Sun, R.-Y., Zhou, D., Han, J., & Wu, Q. (2018) · Cell Research · doi:10.1038/s41422-018-0090-y · Cited by 660
Chowdhry, S., Zhang, Y., McMahon, M., Sutherland, C., Cuadrado, A., & Hayes, J. D. (2013) · Oncogene · doi:10.1038/onc.2012.388 · Cited by 657
“Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?”
BackgroundInfluentialThe Complex Interplay between Antioxidants and ROS in Cancer
Harris, I. S., & DeNicola, G. M. (2020) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.03.002 · Cited by 626
“Support of Tumor Progression by Endogenous Antioxidants On transformation, cells upregulate processes including mitochondrial metabolism [44] and protein translation that lead to increased generation of ROS, necessitating an increased reliance on antioxidants to maintain redox balance [45,46].”
BackgroundWang, Z., Zhang, Y., Ju, E., Liu, Z., Cao, F., Chen, Z., Ren, J., & Qu, X. (2018) · Nature Communications · doi:10.1038/s41467-018-05798-x · Cited by 643
Liu, C., Wang, D., Zhang, S., Cheng, Y., Yang, F., Xing, Y., Xu, T., Dong, H., & Zhang, X. (2019) · ACS Nano · doi:10.1021/acsnano.8b09387 · Cited by 641
Conrad, M., & Sato, H. (2012) · Amino Acids · doi:10.1007/s00726-011-0867-5 · Cited by 598
“Tumor cells generate high amounts of ROS and are therefore well equipped with antioxidant systems (Schumacker 2006; Trachootham et al. 2009).”
BackgroundGong, N., Ma, X., Ye, X., Zhou, Q., Chen, X., Tan, X., Yao, S., Huo, S., Zhang, T., Chen, S., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0373-6 · Cited by 601
Glucose Oxidase‐Instructed Multimodal Synergistic Cancer Therapy
Fu, L., Qi, C., Hu, Y., Lin, J., & Huang, P. (2019) · Advanced Materials · doi:10.1002/adma.201808325 · Cited by 600
Self-citationYang, B., Chen, Y., & Shi, J. (2019) · Advanced Materials · doi:10.1002/adma.201901778 · Cited by 601
The Two Faces of Reactive Oxygen Species in Cancer
Reczek, C. R., & Chandel, N. S. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-041916-065808 · Cited by 602
“ROS accumulation can occur because ROS production is increased or ROS elimination is decreased (Trachootham et al. 2009).”
BackgroundIron‐dependent cell death of hepatocellular carcinoma cells exposed to sorafenib
Louandre, C., Ezzoukhry, Z., Godin, C., Barbare, J., Mazière, J., Chauffert, B., & Galmiche, A. (2013) · International Journal of Cancer · doi:10.1002/ijc.28159 · Cited by 602
“Finally, experimental manipulation of the redox status of cancer cells has been proposed to increase their sensitivity to medical treatments, such as radiation therapy.(33,34) Such strategies might also be useful to increase the cytotoxic effect of sorafenib on HCC cells.”
BackgroundSang, Y., Cao, F., Li, W., Zhang, L., You, Y., Deng, Q., Dong, K., Ren, J., & Qu, X. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b12873 · Cited by 591
Induction of reactive oxygen species: an emerging approach for cancer therapy
Zou, Z., Chang, H., Li, H., & Wang, S. (2017) · Apoptosis · doi:10.1007/s10495-017-1424-9 · Cited by 582
“In addition, higher ROS levels in tumor cells may partly be due to defective mitochondrial oxidative metabolism [1].”
BackgroundInfluentialReactive Oxygen Species (ROS)––Induced genetic and epigenetic alterations in human carcinogenesis
Ziech, D., Franco, R., Pappa, A., & Panayiotidis, M. I. (2011) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2011.02.015 · Cited by 568
Role of Reactive Oxygen Species (ROS) in Therapeutics and Drug Resistance in Cancer and Bacteria
Dharmaraja, A. T. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01243 · Cited by 582
Organoiridium Complexes: Anticancer Agents and Catalysts
Liu, Z., & Sadler, P. J. (2014) · Accounts of Chemical Research · doi:10.1021/ar400266c · Cited by 573
Oxidative stress and dietary phytochemicals: Role in cancer chemoprevention and treatment
Chikara, S., Nagaprashantha, L. D., Singhal, J., Horne, D., Awasthi, S., & Singhal, S. S. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.11.002 · Cited by 559
Cold atmospheric plasma, a novel promising anti-cancer treatment modality
Yan, D., Sherman, J. H., & Keidar, M. (2017) · Oncotarget · doi:10.18632/oncotarget.13304 · Cited by 543
“Due to stronger metabolism in cancer cells, the basal ROS level in cancer cells is thought to be higher than that in normal cells [147-150].”
BackgroundResultAnticancer Activity of Metal Complexes: Involvement of Redox Processes
Jungwirth, U., Kowol, C. R., Keppler, B. K., Hartinger, C. G., Berger, W., & Heffeter, P. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3663 · Cited by 554
“Alterations of the redox status and, consequently, upregulation of oxidative stress and its molecular consequences are well known for malignant tumors and now more and more recognized as platform for the development of novel cancer-targeting drugs (381).”
Cramer, S. L., Saha, A., Liu, J., Tadi, S., Tiziani, S., Yan, W., Triplett, K., Lamb, C., Alters, S. E., Rowlinson, S., et al. (2017) · Nature Medicine · doi:10.1038/nm.4232 · Cited by 538
Self-citationLiu, C., Cao, Y., Cheng, Y., Wang, D., Xu, T., Su, L., Zhang, X., & Dong, H. (2020) · Nature Communications · doi:10.1038/s41467-020-15591-4 · Cited by 542
GSH‐Depleted PtCu3 Nanocages for Chemodynamic‐ Enhanced Sonodynamic Cancer Therapy
Zhong, X., Wang, X., Cheng, L., Tang, Y., Zhan, G., Gong, F., Zhang, R., Hu, J., Liu, Z., & Yang, X. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201907954 · Cited by 541
Defining ROS in Biology and Medicine
Li, Y. R., & Trush, M. (2016) · Reactive Oxygen Species · doi:10.20455/ros.2016.803 · Cited by 481
“Recently, targeting ROS to cancer cells has been developed as a potentially promising strategy for cancer therapy [23].”
BackgroundLiu, T., Liu, W., Zhang, M., Yu, W., Gao, F., Li, C., Wang, S.-B., Feng, J., & Zhang, X.-Z. (2018) · ACS Nano · doi:10.1021/acsnano.8b05860 · Cited by 524
Nogueira, V., & Hay, N. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1424 · Cited by 514
Mitochondrial Dysfunction in Cancer
Boland, M. L., Chourasia, A. H., & Macleod, K. F. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00292 · Cited by 489
“Indeed, many current genotoxic agents used in the clinic, such as cisplatin and certain alkaloids, rely on ROS production for their efficacy (29, 34, 35).”
BackgroundPhotodynamic therapy (PDT) of cancer: from local to systemic treatment
Dabrowski, J. M., & Arnaut, L. G. (2015) · Photochemical & Photobiological Sciences · doi:10.1039/c5pp00132c · Cited by 501
Targeting antioxidants for cancer therapy
Glasauer, A., & Chandel, N. S. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.07.017 · Cited by 499
Convertible Organic Nanoparticles for Near‐Infrared Photothermal Ablation of Cancer Cells
Yang, J., Choi, J., Bang, D., Kim, E., Lim, E., Park, H., Suh, J., Lee, K., Yoo, K., Kim, E., et al. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201005075 · Cited by 515
Theranostic Fluorescent Probes
Sharma, A., Verwilst, P., Li, M., Ma, D., Singh, N., Yoo, J., Kim, Y., Yang, Y., Zhu, J.-H., Huang, H., et al. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00778 · Cited by 499
ROS‐Responsive Polyprodrug Nanoparticles for Triggered Drug Delivery and Effective Cancer Therapy
Xu, X., Saw, P. E., Tao, W., Li, Y., Ji, X., Bhasin, S., Liu, Y., Ayyash, D., Rasmussen, J., Huo, M., et al. (2017) · Advanced Materials · doi:10.1002/adma.201700141 · Cited by 499
Cellular Metabolic Stress: Considering How Cells Respond to Nutrient Excess
Wellen, K. E., & Thompson, C. B. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.10.004 · Cited by 486
“…diseases characterized by altered cellular metabolism, such as cancer and diabetes, are also characterized by elevated ROS levels that may contribute to disease pathogenesis (Brandon et al., 2006; Halliwell, 2007; Nathan, 2008; Roberts and Sindhu, 2009; Trachootham et al., 2009; Wallace, 2005).”
BackgroundInfluentialPike, L. S., Smift, A. L., Croteau, N. J., Ferrick, D. A., & Wu, M. (2011) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2010.10.022 · Cited by 469
A Dual Role of Heme Oxygenase-1 in Cancer Cells
Chiang, S.-K., Chen, S.-E., & Chang, L.-C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010039 · Cited by 465
“However, cancer cells remain to maintain higher ROS production than normal cells [2], and thus a dramatic increase of intracellular ROS still functions to kill cancer cells by shutting down antioxidant systems.”
BackgroundInfluentialNoh, J., Kwon, B., Han, E., Park, M., Yang, W., Cho, W., Yoo, W., Khang, G., & Lee, D. (2015) · Nature Communications · doi:10.1038/ncomms7907 · Cited by 461
Targeting the Thioredoxin System for Cancer Therapy
Zhang, J., Li, X., Han, X., Liu, R., & Fang, J. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.06.001 · Cited by 460
Takaki, A., Kawai, D., & Yamamoto, K. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141020704 · Cited by 447
“Targets Hydrogen Administration Reference Number Disease models Cerebral ischemia reperfusion injury Gas [18] Liver ischemia reperfusion injury Gas [111] Myocardial ischemia reperfusion injury Gas [112] Lung ischemia reperfusion injury Gas [113] Parkinson’s disease Drinking water [114] Atherosclerosis Drinking water […”
BackgroundMethodSelenium, Selenoproteins and Viral Infection
Guillin, O., Vindry, C., Ohlmann, T., & Chavatte, L. (2019) · Nutrients · doi:10.3390/nu11092101 · Cited by 443
“Oxidative stress leads to direct or indirect ROS-mediated damage of nucleic acids, proteins, and lipids, and this phenomenon has been implicated in many pathological conditions including carcinogenesis [36], neurodegeneration [37,38], atherosclerosis, diabetes [39], and aging [40].”
BackgroundBiological and physiological role of reactive oxygen species - the good, the bad and the ugly
Zuo, L., Zhou, T., Pannell, B. K., Ziegler, A. C., & Best, T. M. (2015) · Acta Physiologica · doi:10.1111/apha.12515 · Cited by 427
“Multiple studies have investigated the effectiveness of utilizing ROS for cancer treatment, with a few clinical trials currently in progress (Trachootham et al. 2009).”
BackgroundZhang, W., Hu, X., Shen, Q., & Xing, D. (2019) · Nature Communications · doi:10.1038/s41467-019-09566-3 · Cited by 438
The ever-expanding role of HIF in tumour and stromal biology
LaGory, E. L., & Giaccia, A. J. (2016) · Nature Cell Biology · doi:10.1038/ncb3330 · Cited by 430
Keidar, M. (2015) · Plasma Sources Science and Technology · doi:10.1088/0963-0252/24/3/033001 · Cited by 438
Li, W.-P., Su, C.-H., Chang, Y.-C., Lin, Y.-J., & Yeh, C.-S. (2016) · ACS Nano · doi:10.1021/acsnano.5b06175 · Cited by 437
“overproduction of ROS can result in oxidative damage of cell functions.(17-19) In”
BackgroundDong, Z., Feng, L., Chao, Y., Hao, Y., Chen, M., Gong, F., Han, X., Zhang, R., Cheng, L., & Liu, Z. (2019) · Nano Letters · doi:10.1021/acs.nanolett.8b03905 · Cited by 437
Exosome Biochemistry and Advanced Nanotechnology for Next‐Generation Theranostic Platforms
Yang, B., Chen, Y., & Shi, J. (2019) · Advanced Materials · doi:10.1002/adma.201802896 · Cited by 435
Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy
Meijer, T. W. H., Kaanders, J. H. A. M., Span, P. N., & Bussink, J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0858 · Cited by 433
“As ROS are produced during mitochondrial oxidation, these metabolic alterations could enhance the therapeutic efficacy of radiotherapy (69).”
BackgroundChen, Z., Li, Y., Zhang, H., Huang, P., & Luthra, R. (2010) · Oncogene · doi:10.1038/onc.2010.193 · Cited by 426
“Reactive oxygen species (ROS) can activate various survival pathways, promote genetic instability and render cells resistant to drug treatment (Trachootham et al., 2009).”
BackgroundSelf-citationLow temperature plasma biomedicine: A tutorial review
Graves, D. B. (2014) · Physics of Plasmas · doi:10.1063/1.4892534 · Cited by 417
Van der Paal, J., Neyts, E. C., Verlackt, C. C. W., & Bogaerts, A. (2016) · Chemical Science · doi:10.1039/c5sc02311d · Cited by 413
Hu, Q., Gao, M., Feng, G., & Liu, B. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201408897 · Cited by 419
Metadata
- Authors
- Trachootham, D., Alexandre, J., & Huang, P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Huang, Peng
- Venue
- Nature Reviews Drug Discovery
- Published
- 2009-05-29
- Volume
- 8
- Issue
- 7
- Pages
- 579-591
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1972779889
- Cited by
- 5,452
- References
- 163
- Citations by year
- 2026: 322 · 2025: 332 · 2024: 340 · 2023: 372 · 2022: 421 · 2021: 462 · 2020: 444 · 2019: 454 · 2018: 393 · 2017: 404 · 2016: 341 · 2015: 289 · 2014: 282 · 2013: 204 · 2012: 158
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA085563, R01CA109041, CA109041, R01CA085563, R01CA100428, CA100428)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer and biochemical research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- reactive oxygen species, oxidative stress, redox modulation, cancer cells, drug resistance, antioxidant capacity, anticancer agents, genomic instability
- MeSH terms
- Adaptation, Physiological, Animals, Glutathione, Humans, Neoplasms, Oxidation-Reduction, Neoplastic Stem Cells, Reactive Oxygen Species, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.